DLL3 and small cell lung carcinoma: Despite the cessation of the TAHOE trial, DLL3 remains a high-value target in SCLC due to its high, homogeneous expression on the surface of tumor cells and its low, relatively restricted, cytoplasmic expression in normal cells.